AMY K SHANNON DO
Prescription History 1194798413
General Practice in Cranberry Township, PA

NPI Status: Active since February 08, 2006

Contact Information

2009 MACKENZIE WAY STE 100
CRANBERRY TOWNSHIP, PA
ZIP 16066
Phone: (724) 698-7334

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for AMY K SHANNON DO, an active General Practice specialist practicing in Cranberry Township, PA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 531 documented patient claims. Among these therapy options, the most frequently utilized medication is Buprenorphine-Naloxone, which accounts for 458 claims alone.

Medication Index

No matching medications currently found on file.

Buprenorphine-Naloxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 458
30-Day Fills 458.3
Days Supply 10,385
PA State Average Benchmarks
Peer Average Claims86.0
Peer Average 30-Day Fills86.7
Peer Average Days Supply1,806
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 432.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81,418.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$177.77

State Avg Cost Per Claim

$162.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Suboxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.0
Days Supply 1,051
PA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply642
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 82.1% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,490.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$421.38

State Avg Cost Per Claim

$462.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Zubsolv

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 340
PA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply448
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,841.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$310.99

State Avg Cost Per Claim

$434.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like AMY K SHANNON DO provides transparency into local medical care patterns within Cranberry Township, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **General Practice** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.